




RealRate

PHARMACEUTICAL 2021

Syros Pharmaceuticals Inc.
Rank 192 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Syros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Syros Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -111%, being 243% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	178,557
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,624
Liabilities, Non-Current	0
Other Assets	20,480
Other Compr. Net Income	-1,765
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	14,213
Research and Development	76,065
Revenues	15,093
Selling, General and Administrative Expense	21,325

Output Variable	Value in 1000 USD
Assets	213,250
Liabilities	28,624
Expenses	97,390
Stockholders Equity	184,626
Net Income	-82,297
Comprehensive Net Income	-83,180
Economic Capital Ratio	-111%